<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265264</url>
  </required_header>
  <id_info>
    <org_study_id>BCX4208-203</org_study_id>
    <nct_id>NCT01265264</nct_id>
  </id_info>
  <brief_title>Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol</brief_title>
  <official_title>A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ulodesine and allopurinol combined for 12
      weeks are effective in treating gout in patients who are not adequately responding to
      allopurinol alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the dose response of ulodesine when combined with Allopurinol on sUA.</measure>
    <time_frame>Day 85</time_frame>
    <description>Level of serum uric acid levels be measured at Day 85 to evaluate in subjects with Gout.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <condition>Arthritis</condition>
  <condition>Joint Disease</condition>
  <arm_group>
    <arm_group_label>ulodesine Placebo + Allopurinol 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose administered daily for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ulodesine 5mg + Allopurinol 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose administered daily for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ulodesine 10mg + Allopurinol 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose administered daily for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ulodesine 20mg + Allopurinol 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose administered daily for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ulodesine 40mg + Allopurinol 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose administered daily for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulodesine</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>ulodesine Placebo + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 5mg + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 10mg + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 20mg + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 40mg + Allopurinol 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>ulodesine Placebo + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 5mg + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 10mg + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 20mg + Allopurinol 300mg</arm_group_label>
    <arm_group_label>ulodesine 40mg + Allopurinol 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 to &lt; 70 years

          -  Baseline sUA ≥ 6.0 mg/dL after at least 2 weeks of treatment on a stable 300 mg dose
             of allopurinol

          -  Documented diagnosis of gout according to the American Rheumatism Association
             --Preliminary Criteria for the Diagnosis of Gout

          -  Be willing and able to take colchicine 0.6 mg per day or naproxen 220-250 mg twice
             daily as prophylaxis for gout flares and, if needed, a single daily dose of a proton
             pump inhibitor to prevent gastrointestinal discomfort

          -  Female participants must:

               -  Be sexually abstinent

               -  Be surgically sterile

               -  Be postmenopausal or on stable contraception

          -  Male participants must:

               -  Be sexually abstinent

               -  Be &gt; 1 year post-vasectomy

               -  Using condoms with spermicide with partners meeting female requirements

        Exclusion Criteria:

          -  Unable to tolerate 300 mg allopurinol

          -  Unable to tolerate both colchicine 0.6 mg per day and naproxen 220-250 mg twice daily

          -  Prior participation in a clinical study with BCX4208

          -  Gout flare during the Screening Period that is resolved for less than 2 weeks prior to
             first treatment with BCX4208 or placebo (exclusive of chronic synovitis/ arthritis)

          -  Unstable angina, symptomatic arrhythmia, signs or symptoms compatible with New York
             Heart Association Class III or Class IV heart failure, history of long QT syndrome, or
             QTc interval &lt; 350 msec or &gt; 475 msec

          -  Poorly controlled hypertension (SBP &gt; 160 mmHg or DBP &gt; 100 mmHG at Screening or
             Baseline)

          -  Moderate or severe renal impairment and/or calculated creatinine clearance of &lt; 60
             mL/min(Cockroft-Gault method)

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values &gt; 2.0 x ULN

          -  CD4+ cell counts by flow cytometry &lt; 500 cells/mm3

          -  Hemoglobin &lt; 10 g/dL or &gt; 18 g/dL males or &lt; 10 g/dL or &gt; 17 g/dL females White blood
             cell count &lt; 3.7 x 109/L or &gt; 11 x 109/L

          -  Female subjects who are pregnant, breastfeeding, or planning a pregnancy within the
             next 4 months

          -  Positive serology for hepatitis B surface antigen or hepatitis C or HIV type 1

          -  Immunocompromised or on systemic immunosuppressive medications or antirheumatic drugs
             (including anakinra and adrenocorticotropic hormone)from Screening to Day 92

          -  Azathioprine or 6-mercaptopurine within 14 days of first dose of allopurinol
             Hydrochlorothiazide in doses &gt; 50 mg per day from Screening to Day 92

          -  Use of herbal/dietary supplements Screening to Day 92

          -  Recipient of any live or attenuated vaccine within 6 weeks of Screening

          -  Uric acid-lowering drugs other than allopurinol from Screening to Day 92 Systemic
             corticosteroids within 4 weeks prior to Day 1 (this does not include pulmonary or
             nasal inhaler containing corticosteroids, ophthalmic corticosteroids, joint
             injections, or low potency topical steroids)

          -  Investigational drug within 30 days prior to signing the ICF for this study

          -  Clinically significant and relevant drug allergies

          -  Chronic or recurrent infections (≥ 3 infections at the same site within 12 months)

          -  Cancer within 12 months-Except non-melanomatous localized skin cancer or completely
             excised and cured carcinoma-in-situ of uterine cervix or subjects who were previously
             treated for prostate or breast cancer if they currently are stable and have not been
             on chemo therapy within the last year prior to screening.

          -  Alcohol or drug abuse within 12 months of signing the ICF, or current substance
             dependence or abuse

          -  Other medical conditions which, in the opinion of the PI, would jeopardize the safety
             of the study subject or impact the validity of the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Hollister, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BioCryst Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldsmar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <disposition_first_submitted>October 4, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 4, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 28, 2013</disposition_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>arthritis</keyword>
  <keyword>joint diseases</keyword>
  <keyword>allopurinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

